Clinical data reveals up to 4 years of safety outcomes in patients with ulcerative colitis, suggesting effective long-term management.
Introduction: Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). The long-term safety, tolerability and efficacy of etrasimod are being evaluated in an ongoing open-label extension (OLE) study. [1]
No takes yet. Share an insight, caveat, or question.
Vermeire et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: